Inovio Pharmaceuticals Inc (NASDAQ:INO) was downgraded by stock analysts at BidaskClub from a “hold” rating to a “sell” rating in a research note issued on Monday.

A number of other equities analysts have also commented on the stock. Piper Jaffray Companies upgraded shares of Inovio Pharmaceuticals from a “neutral” rating to an “overweight” rating and set a $14.00 price objective for the company in a research report on Thursday, June 8th. HC Wainwright set a $13.00 price objective on shares of Inovio Pharmaceuticals and gave the company a “buy” rating in a research report on Saturday, June 3rd. Maxim Group restated a “buy” rating and issued a $12.00 price objective on shares of Inovio Pharmaceuticals in a research report on Tuesday, September 12th. Zacks Investment Research upgraded shares of Inovio Pharmaceuticals from a “hold” rating to a “buy” rating and set a $8.75 price objective for the company in a research report on Tuesday, July 11th. Finally, Aegis raised their price objective on shares of Inovio Pharmaceuticals from $11.00 to $14.00 and gave the company a “buy” rating in a research report on Thursday, May 25th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and nine have assigned a buy rating to the stock. Inovio Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $19.80.

Inovio Pharmaceuticals (INO) traded down 2.23% during mid-day trading on Monday, reaching $6.15. 976,264 shares of the company’s stock were exchanged. Inovio Pharmaceuticals has a 52-week low of $5.28 and a 52-week high of $9.86. The stock’s market cap is $554.90 million. The company has a 50-day moving average of $5.73 and a 200-day moving average of $6.65.

Inovio Pharmaceuticals (NASDAQ:INO) last posted its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.08. The firm had revenue of $20.41 million during the quarter, compared to the consensus estimate of $16.29 million. Inovio Pharmaceuticals had a negative net margin of 46.44% and a negative return on equity of 33.16%. The company’s revenue was up 229.2% on a year-over-year basis. During the same quarter last year, the company earned ($0.26) earnings per share. Equities research analysts anticipate that Inovio Pharmaceuticals will post ($0.92) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This article was published by American Banking News and is owned by of American Banking News. If you are reading this article on another website, it was stolen and reposted in violation of international trademark and copyright laws. The correct version of this article can be accessed at https://www.americanbankingnews.com/2017/09/24/inovio-pharmaceuticals-inc-ino-downgraded-to-sell-at-bidaskclub.html.

A number of institutional investors have recently made changes to their positions in INO. Wells Fargo & Company MN lifted its position in Inovio Pharmaceuticals by 28.9% during the first quarter. Wells Fargo & Company MN now owns 124,565 shares of the biopharmaceutical company’s stock valued at $825,000 after purchasing an additional 27,898 shares during the last quarter. Bank of New York Mellon Corp lifted its position in Inovio Pharmaceuticals by 3.6% during the first quarter. Bank of New York Mellon Corp now owns 342,348 shares of the biopharmaceutical company’s stock valued at $2,266,000 after purchasing an additional 11,765 shares during the last quarter. American International Group Inc. lifted its position in Inovio Pharmaceuticals by 7.1% during the first quarter. American International Group Inc. now owns 40,856 shares of the biopharmaceutical company’s stock valued at $270,000 after purchasing an additional 2,695 shares during the last quarter. Vident Investment Advisory LLC lifted its position in Inovio Pharmaceuticals by 20.0% during the first quarter. Vident Investment Advisory LLC now owns 127,375 shares of the biopharmaceutical company’s stock valued at $843,000 after purchasing an additional 21,228 shares during the last quarter. Finally, Teachers Advisors LLC lifted its position in Inovio Pharmaceuticals by 2.3% during the first quarter. Teachers Advisors LLC now owns 151,775 shares of the biopharmaceutical company’s stock valued at $1,005,000 after purchasing an additional 3,411 shares during the last quarter. Institutional investors and hedge funds own 24.83% of the company’s stock.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.

Analyst Recommendations for Inovio Pharmaceuticals (NASDAQ:INO)

Receive News & Ratings for Inovio Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.